XML 29 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details)
 3 Months Ended 9 Months Ended
Mar. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
program
d
$ / shares
shares
May 08, 2017
USD ($)
Dec. 31, 2016
USD ($)
Aug. 31, 2014
USD ($)
$ / shares
shares
Property, Plant and Equipment [Line Items]          
Discrete income tax benefit $ 900,000        
Outstanding warrants to purchase shares of Viking's common stock (shares) | shares         3,264,643
Warrant exercise price (USD per share) | $ / shares         $ 125.08
Note receivable, interest and principal reduction per dollar of value   0.50      
Working capital deficit   $ 7,500,000      
Equity component of currently redeemable convertible notes   $ 21,597,000   $ 29,563,000  
Business days for repayment of principal   3 days      
Consecutive trading days | d   50      
2019 convertible senior notes          
Property, Plant and Equipment [Line Items]          
Principal amount outstanding   $ 245,000,000   245,000,000  
2019 convertible senior notes | Senior Notes          
Property, Plant and Equipment [Line Items]          
Principal amount outstanding         $ 245,000,000.0
Interest rate (as a percent)         0.75%
Retained Earnings | Accounting Standards Update 2016-09          
Property, Plant and Equipment [Line Items]          
Cumulative effect of new accounting principle in period of adoption 17,900,000        
Retained Earnings | Accounting Standards Update 2016-09, Forfeiture Rate Component          
Property, Plant and Equipment [Line Items]          
Cumulative effect of new accounting principle in period of adoption $ 300,000        
Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Equity method investment, ownership (percent)   22.10%      
Market value of investment in Viking   $ 12,000,000      
Outstanding warrants to purchase shares of Viking's common stock (shares) | shares   1,500,000      
Warrant exercise price (USD per share) | $ / shares   $ 1.50      
Number of programs licensed to Viking | program   5      
Note receivable, stated interest rate (percent)   2.50%      
Note Receivable, Cash Repayment Due     $ 200,000    
Fair Value, Measurements, Recurring [Member]          
Property, Plant and Equipment [Line Items]          
Assets, fair value   $ 173,637,000   126,187,000  
Fair Value, Measurements, Recurring [Member] | Investment in warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   1,110,000   684,000  
Fair Value, Measurements, Recurring [Member] | Note receivable Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Assets, fair value   3,007,000   3,207,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1          
Property, Plant and Equipment [Line Items]          
Assets, fair value   3,863,000   3,738,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 | Investment in warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   1,100,000   700,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 | Note receivable Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Assets, fair value   0   0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3          
Property, Plant and Equipment [Line Items]          
Assets, fair value   3,007,000   3,207,000  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 | Investment in warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   0   0  
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 | Note receivable Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Assets, fair value   $ 3,000,000   $ 3,207,000